Stocktoria

GOLDENWELL BIOTECH, INC. GWLL

OTC · stock · Food and Kindred Products · website · IPO 2021-12-07

GOLDENWELL BIOTECH, INC. (GWLL) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2024 revenue was $139 at a -94602.9% net margin.

3/9
Piotroski F — financial health
Altman Z″ — distress risk
Dividend payout · no dividend
$0.52 as of 2026-06-01 · +160% 1y
$0.20$7.0052-wk

Price from month-end closes (Yahoo) — for reference, not real-time.

Net margin-94602.9%
Revenue trend · last 6y · up

How it ranks in Manufacturing · percentile among 1906 companies

Piotroski Fstronger than 27%
Net marginstronger than 1%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 3/9 tests passed

Sector peers · similar-size Manufacturing companies

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
GWLLGOLDENWELL BIOTECH, INC.3/9
SOWGSow Good Inc.1/9
TRWDTradewinds Universal3/9
NXMHNext Meats Holdings, Inc.1/9
BOFBranchOut Food Inc.3/9-7.44
CHSNChanson International Holding4/91.9220.4+0.2%
BRLSBorealis Foods Inc.4/9-16.21+8.2%

All Manufacturing companies →

FAQ

Is GWLL financially healthy?

GOLDENWELL BIOTECH, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).

Does GWLL pay a dividend?

No, GOLDENWELL BIOTECH, INC. does not currently pay a dividend.

How profitable is GWLL?

In FY2024, GOLDENWELL BIOTECH, INC. had a net margin of -94602.9%.

Source: SEC EDGAR filings · CIK 0001800373 · US · as of 2024-12-31. facts plus Stocktoria's own computed scores — not investment advice.